Quantcast

Latest Organofluorides Stories

2014-04-04 23:40:13

MedicationDiscountCard.com now makes depression medications more accessible. Margate, NJ (PRWEB) April 03, 2014 Depression continues to be a serious issue plaguing Americans, in spite of the fact that treatment options are more advanced than ever. The Centers for Disease Control and Prevention estimates that more than half of those diagnosed with depression go untreated, while many more are unable to afford the medications they are prescribed. However, there are resources to help save...

2014-04-04 23:01:22

The Firm is actively filing Risperdal lawsuits on behalf of men and boys who allegedly suffered gynecomastia, or male breast development, due to their use of Risperdal. New York, New York (PRWEB) April 04, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the Arkansas Attorney General has announced his intention to seek the reinstatement of a $1.2 billion Risperdal fine overturned by the state’s...

2014-04-03 12:27:08

Lipoglycopeptides Dalvance and Oritavancin Will Find Favorable Uptake as Convenient Outpatient Anti-MRSA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that following its launch, Cubist's second generation oxazolidinone Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus) agents for the treatment of complicated skin and skin structure infections...

2014-04-02 23:01:07

The Firm continues to investigate Risperdal lawsuits that allege the atypical antipsychotic drug caused male breast development, or gynecomastia. New York, New York (PRWEB) April 02, 2014 The nationwide law firm of Bernstein Liebhard LLP is actively filing Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) on behalf of individuals who allegedly suffered gynecomastia, or male breast growth, due to their use of the atypical antipsychotic. On March 26, 2014, the Firm filed a claim...

2014-04-01 08:27:28

LONDON, April 1, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Inhalation & Nasal Spray Generic Drugs 2013 Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted combined revenues of around US$18.0 billion in 2012. All five are...

2014-03-31 23:25:06

The Firm is evaluating Risperdal lawsuits on behalf of men and boys who allegedy developed gynecomastia (male breast growth) due to Risperdal. New York, NY (PRWEB) March 31, 2014 Plaintiffs in hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) pending in Pennsylvania’s Philadelphia Court of Common Pleas are urging the Court to reject Johnson & Johnson’s bid for summary judgment on punitive damages in claims involving Risperdal and gynecomastia, or male breast...

2014-03-30 23:21:40

Data includes how to contact national network of attorneys for no-cost consultations to consumers seeking compensation over allegations that children suffered birth defects due to mothers’ use of Zoloft, Prozac, Celexa, Luvox, Paxil, Lexapro or Viibryd during pregnancies. San Diego, CA (PRWEB) March 30, 2014 http://www.resource4thepeople.com/defectivedrugs/SSRI-Birth-Defects.html Resource4thePeople announced today that it has established an information site for consumers who are...

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

2014-03-28 08:27:31

SentiKin(TM), Kindred Bio's third lead product candidate, is being developed for the treatment of post-operative pain in dogs. SAN FRANCISCO, March 28, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs. SentiKin is a centrally acting non-opioid, non-steroidal...

2014-03-27 08:33:33

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/djkgl4/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide,...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.